Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Depressive Disorder, Treatment-Resistant

Open-data reference.

9 US clinical trials · 3 currently recruiting

Active & Recent Trials

RECRUITING Phase 2 153 participants

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

ACADIA Pharmaceuticals

NCT07284667

RECRUITING Phase 2 50 participants

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

National Institute of Mental Health (NIMH)

NCT06511908

RECRUITING Phase 2 30 participants

Intravenous Ketamine for Treatment-Resistant Depression

Mayo Clinic

NCT06668571

ACTIVE NOT RECRUITING Phase 2 100 participants

Dopaminergic Dysfunction in Late-Life Depression

Vanderbilt University Medical Center

NCT04469959

ACTIVE NOT RECRUITING 54 participants

Improving Brain Stimulation Through Imaging

VA Office of Research and Development

NCT03851380

ACTIVE NOT RECRUITING NA 25 participants

Adaptive tDCS for Treatment-Resistant MDD

Washington University School of Medicine

NCT02942368

COMPLETED Phase 3 1,148 participants

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Janssen Research & Development

NCT02782104

COMPLETED Phase 3 252 participants

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Janssen Research & Development

NCT03434041

COMPLETED Phase 2 206 participants

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Avanir Pharmaceuticals

NCT02153502

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 2

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Depressive Disorder, Treatment-Resistant Trial Landscape

ClinicalTrials.gov lists 9 US studies indexed under Depressive Disorder, Treatment-Resistant, and 3 of those are currently open to recruitment — roughly 33% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Depressive Disorder, Treatment-Resistant shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 5 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Depressive Disorder, Treatment-Resistant is led by Janssen Research & Development with 2 indexed trials, alongside 7 other organizations in the top contributor list. The list on this page surfaces up to 9 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Depressive Disorder, Treatment-Resistant?

PlainTrial tracks 9 US clinical trials for Depressive Disorder, Treatment-Resistant, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Depressive Disorder, Treatment-Resistant?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →